* Kite Pharma presents results of multi-center pivotal
ZUMA-1 trial of Axicabtagene Ciloleucel (KTE-C19) in aggressive
non-hodgkin lymphoma as late-breaking abstract at annual meeting
of American…
The post BRIEF-Kite Pharma presents results of multi-center pivotal Zuma-1 trial of Axicabtagene Ciloleucel (KTE-C19) appeared first on NASDAQ.